Norepinephrine transporter-deficient mice respond to anxiety producing and fearful environments with bradycardia and hypotension

N. R. Keller, A. Diedrich, M. Appalsamy, L. C. Miller, M. G. Caron, Michael Mcdonald, R. C. Shelton, R. D. Blakely, D. Robertson

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The study of anxiety and fear involves complex interrelationships between psychiatry and the autonomic nervous system. Altered noradrenergic signaling is linked to certain types of depression and anxiety disorders, and treatment often includes specific transporter blockade. The norepinephrine transporter is crucial in limiting catecholaminergic signaling. Norepinephrine transporter-deficient mice have increased circulating catecholamines and elevated heart rate and blood pressure. We hypothesized, therefore, that reduced norepinephrine clearance would heighten the autonomic cardiovascular response to anxiety and fear. In separate experiments, norepinephrine transporter-deficient (norepinephrine transporter-/-) mice underwent tactile startle and trace fear conditioning to measure hemodynamic responses. A dramatic tachycardia was observed in norepinephrine transporter-/- mice compared with controls following both airpuff or footshock stimuli, and pressure changes were also greater. Interestingly, in contrast to normally elevated home cage levels in norepinephrine transporter-deficient mice, prestimulus heart rate and blood pressure were actually higher in norepinephrine transporter+/+ animals throughout behavioral testing. Upon placement in the behavioral chamber, norepinephrine transporter-deficient mice demonstrated a notable bradycardia and depressor effect that was more pronounced in females. Power spectral analysis indicated an increase in low frequency oscillations of heart rate variability; in mice, suggesting increased parasympathetic tone. Finally, norepinephrine transporter-/- mice exhibited sexual dimorphism in freeze behavior, which was greatest in females. Therefore, while reduced catecholamine clearance amplifies immediate cardiovascular responses to anxiety- or fear-inducing stimuli in norepinephrine transporter-/- mice, norepinephrine transporter deficiency apparently prevents protracted hemodynamic escalation in a fearful environment. Conceivably, chronic norepinephrine transporter blockade with transporter-specific drugs might attenuate recognition of autonomic and somatic distress signals in individuals with anxiety disorders, possibly lessening their behavioral reactivity, and reducing the cardiovascular risk factors associated with persistent emotional arousal.

Original languageEnglish (US)
Pages (from-to)931-946
Number of pages16
JournalNeuroscience
Volume139
Issue number3
DOIs
StatePublished - May 5 2006

Fingerprint

Norepinephrine Plasma Membrane Transport Proteins
Bradycardia
Hypotension
Anxiety
Fear
Heart Rate
Anxiety Disorders
Catecholamines
Hemodynamics
Blood Pressure
Autonomic Nervous System
Touch
Arousal
Tachycardia
Sex Characteristics
Psychiatry
Norepinephrine

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)

Cite this

Norepinephrine transporter-deficient mice respond to anxiety producing and fearful environments with bradycardia and hypotension. / Keller, N. R.; Diedrich, A.; Appalsamy, M.; Miller, L. C.; Caron, M. G.; Mcdonald, Michael; Shelton, R. C.; Blakely, R. D.; Robertson, D.

In: Neuroscience, Vol. 139, No. 3, 05.05.2006, p. 931-946.

Research output: Contribution to journalArticle

Keller, NR, Diedrich, A, Appalsamy, M, Miller, LC, Caron, MG, Mcdonald, M, Shelton, RC, Blakely, RD & Robertson, D 2006, 'Norepinephrine transporter-deficient mice respond to anxiety producing and fearful environments with bradycardia and hypotension', Neuroscience, vol. 139, no. 3, pp. 931-946. https://doi.org/10.1016/j.neuroscience.2006.01.008
Keller, N. R. ; Diedrich, A. ; Appalsamy, M. ; Miller, L. C. ; Caron, M. G. ; Mcdonald, Michael ; Shelton, R. C. ; Blakely, R. D. ; Robertson, D. / Norepinephrine transporter-deficient mice respond to anxiety producing and fearful environments with bradycardia and hypotension. In: Neuroscience. 2006 ; Vol. 139, No. 3. pp. 931-946.
@article{d5f3a284088f411bbf4d25c2588ed065,
title = "Norepinephrine transporter-deficient mice respond to anxiety producing and fearful environments with bradycardia and hypotension",
abstract = "The study of anxiety and fear involves complex interrelationships between psychiatry and the autonomic nervous system. Altered noradrenergic signaling is linked to certain types of depression and anxiety disorders, and treatment often includes specific transporter blockade. The norepinephrine transporter is crucial in limiting catecholaminergic signaling. Norepinephrine transporter-deficient mice have increased circulating catecholamines and elevated heart rate and blood pressure. We hypothesized, therefore, that reduced norepinephrine clearance would heighten the autonomic cardiovascular response to anxiety and fear. In separate experiments, norepinephrine transporter-deficient (norepinephrine transporter-/-) mice underwent tactile startle and trace fear conditioning to measure hemodynamic responses. A dramatic tachycardia was observed in norepinephrine transporter-/- mice compared with controls following both airpuff or footshock stimuli, and pressure changes were also greater. Interestingly, in contrast to normally elevated home cage levels in norepinephrine transporter-deficient mice, prestimulus heart rate and blood pressure were actually higher in norepinephrine transporter+/+ animals throughout behavioral testing. Upon placement in the behavioral chamber, norepinephrine transporter-deficient mice demonstrated a notable bradycardia and depressor effect that was more pronounced in females. Power spectral analysis indicated an increase in low frequency oscillations of heart rate variability; in mice, suggesting increased parasympathetic tone. Finally, norepinephrine transporter-/- mice exhibited sexual dimorphism in freeze behavior, which was greatest in females. Therefore, while reduced catecholamine clearance amplifies immediate cardiovascular responses to anxiety- or fear-inducing stimuli in norepinephrine transporter-/- mice, norepinephrine transporter deficiency apparently prevents protracted hemodynamic escalation in a fearful environment. Conceivably, chronic norepinephrine transporter blockade with transporter-specific drugs might attenuate recognition of autonomic and somatic distress signals in individuals with anxiety disorders, possibly lessening their behavioral reactivity, and reducing the cardiovascular risk factors associated with persistent emotional arousal.",
author = "Keller, {N. R.} and A. Diedrich and M. Appalsamy and Miller, {L. C.} and Caron, {M. G.} and Michael Mcdonald and Shelton, {R. C.} and Blakely, {R. D.} and D. Robertson",
year = "2006",
month = "5",
day = "5",
doi = "10.1016/j.neuroscience.2006.01.008",
language = "English (US)",
volume = "139",
pages = "931--946",
journal = "Neuroscience",
issn = "0306-4522",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Norepinephrine transporter-deficient mice respond to anxiety producing and fearful environments with bradycardia and hypotension

AU - Keller, N. R.

AU - Diedrich, A.

AU - Appalsamy, M.

AU - Miller, L. C.

AU - Caron, M. G.

AU - Mcdonald, Michael

AU - Shelton, R. C.

AU - Blakely, R. D.

AU - Robertson, D.

PY - 2006/5/5

Y1 - 2006/5/5

N2 - The study of anxiety and fear involves complex interrelationships between psychiatry and the autonomic nervous system. Altered noradrenergic signaling is linked to certain types of depression and anxiety disorders, and treatment often includes specific transporter blockade. The norepinephrine transporter is crucial in limiting catecholaminergic signaling. Norepinephrine transporter-deficient mice have increased circulating catecholamines and elevated heart rate and blood pressure. We hypothesized, therefore, that reduced norepinephrine clearance would heighten the autonomic cardiovascular response to anxiety and fear. In separate experiments, norepinephrine transporter-deficient (norepinephrine transporter-/-) mice underwent tactile startle and trace fear conditioning to measure hemodynamic responses. A dramatic tachycardia was observed in norepinephrine transporter-/- mice compared with controls following both airpuff or footshock stimuli, and pressure changes were also greater. Interestingly, in contrast to normally elevated home cage levels in norepinephrine transporter-deficient mice, prestimulus heart rate and blood pressure were actually higher in norepinephrine transporter+/+ animals throughout behavioral testing. Upon placement in the behavioral chamber, norepinephrine transporter-deficient mice demonstrated a notable bradycardia and depressor effect that was more pronounced in females. Power spectral analysis indicated an increase in low frequency oscillations of heart rate variability; in mice, suggesting increased parasympathetic tone. Finally, norepinephrine transporter-/- mice exhibited sexual dimorphism in freeze behavior, which was greatest in females. Therefore, while reduced catecholamine clearance amplifies immediate cardiovascular responses to anxiety- or fear-inducing stimuli in norepinephrine transporter-/- mice, norepinephrine transporter deficiency apparently prevents protracted hemodynamic escalation in a fearful environment. Conceivably, chronic norepinephrine transporter blockade with transporter-specific drugs might attenuate recognition of autonomic and somatic distress signals in individuals with anxiety disorders, possibly lessening their behavioral reactivity, and reducing the cardiovascular risk factors associated with persistent emotional arousal.

AB - The study of anxiety and fear involves complex interrelationships between psychiatry and the autonomic nervous system. Altered noradrenergic signaling is linked to certain types of depression and anxiety disorders, and treatment often includes specific transporter blockade. The norepinephrine transporter is crucial in limiting catecholaminergic signaling. Norepinephrine transporter-deficient mice have increased circulating catecholamines and elevated heart rate and blood pressure. We hypothesized, therefore, that reduced norepinephrine clearance would heighten the autonomic cardiovascular response to anxiety and fear. In separate experiments, norepinephrine transporter-deficient (norepinephrine transporter-/-) mice underwent tactile startle and trace fear conditioning to measure hemodynamic responses. A dramatic tachycardia was observed in norepinephrine transporter-/- mice compared with controls following both airpuff or footshock stimuli, and pressure changes were also greater. Interestingly, in contrast to normally elevated home cage levels in norepinephrine transporter-deficient mice, prestimulus heart rate and blood pressure were actually higher in norepinephrine transporter+/+ animals throughout behavioral testing. Upon placement in the behavioral chamber, norepinephrine transporter-deficient mice demonstrated a notable bradycardia and depressor effect that was more pronounced in females. Power spectral analysis indicated an increase in low frequency oscillations of heart rate variability; in mice, suggesting increased parasympathetic tone. Finally, norepinephrine transporter-/- mice exhibited sexual dimorphism in freeze behavior, which was greatest in females. Therefore, while reduced catecholamine clearance amplifies immediate cardiovascular responses to anxiety- or fear-inducing stimuli in norepinephrine transporter-/- mice, norepinephrine transporter deficiency apparently prevents protracted hemodynamic escalation in a fearful environment. Conceivably, chronic norepinephrine transporter blockade with transporter-specific drugs might attenuate recognition of autonomic and somatic distress signals in individuals with anxiety disorders, possibly lessening their behavioral reactivity, and reducing the cardiovascular risk factors associated with persistent emotional arousal.

UR - http://www.scopus.com/inward/record.url?scp=33646129453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646129453&partnerID=8YFLogxK

U2 - 10.1016/j.neuroscience.2006.01.008

DO - 10.1016/j.neuroscience.2006.01.008

M3 - Article

C2 - 16515844

AN - SCOPUS:33646129453

VL - 139

SP - 931

EP - 946

JO - Neuroscience

JF - Neuroscience

SN - 0306-4522

IS - 3

ER -